Journal of Shanghai Jiao Tong University (Medical Science) >

2022 , Vol. 42 >Issue 5: 609 - 616

DOI: https://doi.org/10.3969/j.issn.1674-8115.2022.05.008

Clinical research

Analysis of genetic and clinical characteristics of PMP22-associated peripheral neuropathy

  • Xiaowei ZHU ,
  • Feixia ZHAN ,
  • Chao ZHANG ,
  • Shihua LIU ,
  • Ping ZHONG ,
  • Li CAO ,
  • Xinghua LUAN
Expand
  • 1.Department of Neurology, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China
    2.Department of Neurology, Suzhou Hospital of Anhui Medical University, Suzhou 234000, China
LUAN Xinghua, E-mail: green_lxh@sina.com.

Received date: 2021-12-06

  Accepted date: 2022-05-06

  Online published: 2022-05-28

Supported by

National Natural Science Foundation of China(81870889)

Fold

Abstract

Objective

·To investigate the genetic and clinical features of peripheral neuropathy patients with PMP22 gene variations and the association between genotype and clinical phenotype.

Methods

·A total of 162 patients with peripheral neuropathy who were treated in Department of Neurology, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine from 2006 to 2022 were collected. Molecular detecting techniques including combining multiplex ligation-dependent probe amplification (MLPA), whole exon sequencing (WES) and Sanger sequencing were used to comprehensively analyze the genetic variation of 162 patients, and 26 probands with PMP22 gene variations and their 33 family members were screened out. The genetic variations included duplication, deletion and point mutations. The clinical and genetic characteristics of 26 patients with PMP22-associated peripheral neuropathy were further analyzed. The clinical characteristics included clinical demographic data, clinical manifestations, electrophysiological and pathological characteristics.

Results

·There were a total of 59 (37 male and 22 female) individuals with PMP22-associated peripheral neuropathy, among whom 46 patients in 13 families had positive family histories and 13 did not. The median age at onset of neuropathy was 34.0 (14.0, 49.5) years old. The initial symptom was limb weakness or limb numbness. There were 51 Charcot-Marie-Tooth type-1A (CMT1A) patients with PMP22 duplication, 6 hereditary neuropathy with liability to pressure palsies (HNPP) patients with PMP22 deletion and 2 Dejerine-Sottas syndrome (DSS) patients with PMP22 point mutations (p.S72L and p.G100V). Sixteen patients underwent electrophysiological detections. Compared with the 4 PMP22 deletion patients, the motor nerve conduction velocity (MCV), compound muscle action potential (CMAP) and sensory nerve conduction velocities (SCV) of 12 PMP22 duplication patients were obviously decreased (all P<0.05). Conduction block was found in both kinds of mutation types. Sural nerve biopsies were performed in 12 patients, including 8 PMP22 duplication, 3 PMP22 deletion and 1 PMP22 point mutation, and pathological changes such as thinning of myelinated nerve fibers, “onion bulbs” and decreased nerve fiber density were observed in varying degrees.

Conclusion

·PMP22 gene-associated neuropathies can be characterized by CMT1A, HNPP and DSS with high clinical heterogeneity. Patients with demyelinating manifestations on electrophysiological detections and sural nerve biopsy need genetic testing for PMP22 gene duplication, deletion and point mutation after ruling out acquired etiology. It is available to help optimize diagnosis and genetic counseling of the disease.

Key words： Charcot-Marie-Tooth type-1A (CMT1A); hereditary neuropathy with liability to pressure palsies (HNPP); Dejerine-Sottas syndrome (DSS); PMP22 gene; mutation

Cite this article

Xiaowei ZHU , Feixia ZHAN , Chao ZHANG , Shihua LIU , Ping ZHONG , Li CAO , Xinghua LUAN . Analysis of genetic and clinical characteristics of PMP22-associated peripheral neuropathy[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022 , 42(5) : 609 -616 . DOI: 10.3969/j.issn.1674-8115.2022.05.008

References

1 PANTERA H, MORAN J J, HUNG H A, et al. Regulation of the neuropathy-associated Pmp22 gene by a distal super-enhancer[J]. Hum Mol Genet, 2018, 27(16): 2830-2839.
2 LIU X X, DUAN X H, ZHANG Y S, et al. Clinical and genetic diversity of PMP22 mutations in a large cohort of Chinese patients with Charcot-Marie-tooth disease[J]. Front Neurol, 2020, 11: 630.
3 朱啸巍, 钟平, 栾兴华. PMP22相关性周围神经病的临床及遗传学特点[J]. 中国实用神经疾病杂志, 2021, 24(14): 1265-1270.
3 ZHU X W, ZHONG P, LUAN X H. The clinical and genetic characteristics of PMP22-associated peripheral neuropathy[J]. Chin J Pract Nerv Dis, 2021, 24(14): 1265-1270.
4 GENTILE L, RUSSO M, FABRIZI G M, et al. Charcot-Marie-Tooth disease: experience from a large Italian tertiary neuromuscular center[J]. Neurol Sci, 2020, 41(5): 1239-1243.
5 WATILA M M, BALARABE S A. Molecular and clinical features of inherited neuropathies due to PMP22 duplication[J]. J Neurol Sci, 2015, 355(1/2): 18-24.
6 IVANOVIC V, BRANKOVIC M, BJELICA B, et al. Yield of the PMP22 deletion analysis in patients with compression neuropathies[J]. J Neurol, 2020, 267(12): 3617-3623.
7 D'ARRIGO S, TESSAROLLO V, TARONI F, et al. A case of severe early-onset neuropathy caused by a compound heterozygous deletion of the PMP22 gene: clinical and neurographic aspects[J]. Neuropediatrics, 2020, 51(3): 173-177.
8 MORINI A, MALAGUTI M C, MARANGONI S, et al. Neuropathic tremor in chronic inflammatory demyelinating polyneuropathy: the acquired equivalent of the roussy-levy syndrome[J]. Mov Disord Clin Pract, 2015, 3(2): 173-175.
9 徐佳露, 章毅, 赵聪颖, 等. 13例早发型腓骨肌萎缩症的基因分型研究[J]. 中国当代儿科杂志, 2019, 21(7): 670-675.
9 XU J L, ZHANG Y, ZHAO C Y, et al. A genotyping study of 13 cases of early-onset Charcot-Marie-Tooth disease[J]. Chin J Contemp Pediat, 2019, 21(7): 670-675.
10 ROA B B, DYCK P J, MARKS H G, et al. Dejerine-Sottas syndrome associated with point mutation in the peripheral myelin protein 22 (PMP22) gene[J]. Nat Genet, 1993, 5(3): 269-273.
11 MARQUES W Jr, THOMAS P K, SWEENEY M G, et al. Dejerine-Sottas neuropathy and PMP22 point mutations: a new base pair substitution and a possible “hot spot” on Ser72[J]. Ann Neurol, 1998, 43(5): 680-683.
12 RUSSO M, LAURá M, POLKE J M, et al. Variable phenotypes are associated with PMP22 missense mutations[J]. Neuromuscul Disord, 2011, 21(2): 106-114.
13 RICHARDS S, AZIZ N, BALE S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015, 17(5): 405-424.
14 WU R, LV H, ZHANG W, et al. Clinical and pathological variation of Charcot-Marie-tooth 1A in a large Chinese cohort[J]. Biomed Res Int, 2017, 2017: 6481367.
15 LOUSA M, VáZQUEZ-HUARTE-MENDICOA C, GUTIéRREZ A J, et al. Genetic epidemiology, demographic, and clinical characteristics of Charcot-Marie-tooth disease in the island of Gran Canaria (Spain)[J]. J Peripher Nerv Syst, 2019, 24(1): 131-138.
16 BRO?KOVá D, MAZANEC R, RYCHLY Z, et al. Four novel point mutations in the PMP22 gene with phenotypes of HNPP and Dejerine-Sottas neuropathy[J]. Muscle Nerve, 2011, 44(5): 819-822.
17 AZEVEDO H, PUPE C, PEREIRA R, et al. Pain in Charcot-Marie-Tooth disease: an update[J]. Arq Neuropsiquiatr, 2018, 76(4): 273-276.
18 KAWARAI T, YAMAZAKI H, MIYAMOTO R, et al. PMP22-related disease: a novel splice site acceptor variant and intrafamilial phenotype variability[J]. Neuromuscul Disord, 2019, 29(6): 422-426.
19 MITTENDORF K F, MARINKO J T, HAMPTON C M, et al. Peripheral myelin protein 22 alters membrane architecture[J]. Sci Adv, 2017, 3(7): e1700220.
20 ZHOU Y, MILES J R, TAVORI H, et al. PMP22 regulates cholesterol trafficking and ABCA1-mediated cholesterol efflux[J]. J Neurosci, 2019, 39(27): 5404-5418.
21 SVAREN J, MORAN J J, WU X Y, et al. Schwann cell transcript biomarkers for hereditary neuropathy skin biopsies[J]. Ann Neurol, 2019, 85(6): 887-898.
22 PANTERA H, SHY M E, SVAREN J. Regulating PMP22 expression as a dosage sensitive neuropathy gene[J]. Brain Res, 2020, 1726: 146491.
23 LI J. Genetic factors for nerve susceptibility to injuries: lessons from PMP22 deficiency[J]. Neural Regen Res, 2014, 9(18): 1661-1664.
24 TYSON J, ELLIS D, FAIRBROTHER U, et al. Hereditary demyelinating neuropathy of infancy. A genetically complex syndrome[J]. Brain, 1997, 120 ( Pt 1): 47-63.
25 NELIS E, HAITES N, VAN BROECKHOVEN C. Mutations in the peripheral myelin genes and associated genes in inherited peripheral neuropathies[J]. Hum Mutat, 1999, 13(1): 11-28.
26 WU R, FU J, MENG L C, et al. Homozygous splice-site mutation c.78+5G>A in PMP22 causes congenital hypomyelinating neuropathy[J]. Neuropathology, 2019, 39(6): 441-446.
27 LIAO Y C, TSAI P C, LIN T S, et al. Clinical and molecular characterization of PMP22 point mutations in Taiwanese patients with inherited neuropathy[J]. Sci Rep, 2017, 7(1): 15363.
28 RAMCHANDREN S. Charcot-Marie-tooth disease and other genetic polyneuropathies[J]. Continuum (Minneap Minn), 2017, 23(5, Peripheral Nerve and Motor Neuron Disorders): 1360-1377.
29 NAGAPPA M, SHARMA S, GOVINDARAJ P, et al. PMP22 gene-associated neuropathies: phenotypic spectrum in a cohort from India[J]. J Mol Neurosci, 2020, 70(5): 778-789.
30 ABE A, NAKAMURA K, KATO M, et al. Compound heterozygous PMP22 deletion mutations causing severe Charcot-Marie-Tooth disease type 1[J]. J Hum Genet, 2010, 55(11): 771-773.
31 AGOSTONI E, GOBESSI S, BRANCOLINI C, et al. Identification and characterization of a new member of the gas3/PMP22 gene family in C. elegans[J]. Gene, 1999, 234(2): 267-274.
32 ABE K T, LINO A M M, HIRATA M T A, et al. A novel stop codon mutation in the PMP22 gene associated with a variable phenotype[J]. Neuromuscul Disord, 2004, 14(5): 313-320.
33 TRACY J A, DYCK P J, KLEIN C J, et al. Onion-bulb patterns predict acquired or inherited demyelinating polyneuropathy[J]. Muscle Nerve, 2019, 59(6): 665-670.
34 MOSS K R, BOPP T S, JOHNSON A E, et al. New evidence for secondary axonal degeneration in demyelinating neuropathies[J]. Neurosci Lett, 2021, 744: 135595.
35 ZHAO H T, DAMLE S, IKEDA-LEE K, et al. PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models[J]. J Clin Invest, 2018, 128(1): 359-368.
Options
Outlines

/

〈 〉